ALA Stock Overview
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally.
Arovella Therapeutics Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.026|
|52 Week High||AU$0.055|
|52 Week Low||AU$0.02|
|1 Month Change||0%|
|3 Month Change||8.33%|
|1 Year Change||-25.71%|
|3 Year Change||-60.61%|
|5 Year Change||-93.50%|
|Change since IPO||-99.41%|
Recent News & Updates
|ALA||AU Pharmaceuticals||AU Market|
Return vs Industry: ALA underperformed the Australian Pharmaceuticals industry which returned -23.7% over the past year.
Return vs Market: ALA underperformed the Australian Market which returned -1.8% over the past year.
|ALA Average Weekly Movement||14.7%|
|Pharmaceuticals Industry Average Movement||10.2%|
|Market Average Movement||9.0%|
|10% most volatile stocks in AU Market||15.9%|
|10% least volatile stocks in AU Market||4.1%|
Stable Share Price: ALA is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: ALA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.
Arovella Therapeutics Limited Fundamentals Summary
|ALA fundamental statistics|
Is ALA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALA income statement (TTM)|
|Cost of Revenue||AU$207.06k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.013|
|Net Profit Margin||-2,876.84%|
How did ALA perform over the long term?See historical performance and comparison